Replies to post #207527 on Biotech Values

[Bickema]

"51.4% of subjects discontinued prematurely from the study"

now down to 1.30's wow, Co. still plans to resubmit an NDA based off these results

[DewDiligence]

AGRX—(-21%/PM)—sells 6.13M* shares @$3.50—a 23% discount to yesterdays’ close:

https://finance.yahoo.com/news/agile-therapeutics-announces-pricing-public-122425390.html

*Assuming exercise of underwriter’s option.